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According to GLOBOCAN, colorectal cancer (CRC) is the third 
most common cancer and the fourth most common cause of cancer-
related death, with 1.85 million new cases diagnosed worldwide 
in 2018.[1,2] The incidence of CRC appears to be increasing in 
emerging low- and middle-income countries (LMICs) owing to 
socioepidemiological transitions, including dietary changes, with 
countries in sub-Saharan Africa (SSA) reporting a notable increase 
in colorectal, breast and prostate cancer.[3,4] South Africa (SA) is 
no exception – the incidence of CRC is increasing steadily, and it 
was the sixth leading cause of cancer-related death in 2018.[1] It is 
noteworthy that apart from increasing incidence, the average age of 
CRC patients at the time of diagnosis in SSA is ~10 years younger 
than that observed in high-income countries (HICs).[5,6] In addition, 
other non-communicable diseases (NCDs), including diabetes and 
respiratory and cardiovascular disease, are on the rise, with the 
prevalence in SA being reported as two to three times higher than 
in HICs.[7]
While there are no published data on comorbidity with CRC 
from SSA, many CRC cohorts from HICs describe a considerable 
comorbidity burden that adversely affects short- (30-day) and long-
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Background. The Colorectal Cancer South Africa (CRCSA) study is an observational cohort of patients with colorectal cancer (CRC) in 
Johannesburg, South Africa (SA). We found that the mean age at the time of CRC diagnosis was 56.6 years, consistent with studies from SA 
and sub-Saharan Africa. In high-income settings, comorbidity adversely affects CRC survival, and patients are substantially older at the time 
of CRC diagnosis. Given the younger age at CRC diagnosis in the CRCSA cohort, we hypothesised that comorbidity may be less prevalent 
and have little impact on CRC survival.
Objectives. To determine the prevalence of comorbidity and whether comorbidity adversely affects overall survival (OS) of CRC patients.
Methods. Patients enrolled in the CRCSA study between January 2016 and July 2018 were included. The cohort comprised a convenience 
sample of adults with histologically confirmed CRC, treated at the University of the Witwatersrand Academic Teaching Hospital Complex. 
Demographic, clinical and histological variables were collected at baseline and participants were followed up for OS. The Charlson 
comorbidity index (CCI) scoring system was used to classify participants as ‘no comorbidity’ (CCI score 0) and ‘1 or more comorbidities’ 
(CCI score ≥1). A descriptive analysis of the cohort was undertaken, while survival across comorbidity groups was compared by the Kaplan-
Meier method and Cox proportional hazards (PH) regression models. Multivariable Cox PH regression was performed to examine the effect 
of comorbidity on survival (unadjusted) and then adjusted for variables.
Results. There were 424 participants, and the mean (standard deviation) age was 56.6 (14.1) years (range 18 - 91). Only 19.1% of participants 
had ≥1 comorbidities, of which diabetes mellitus was most frequent (12.3%), followed by chronic obstructive pulmonary disease (4.7%) 
and cardiovascular disease (3.1%). There was no significant difference in unadjusted and adjusted risk of death for the group with 
≥1 comorbidities compared with those with no comorbidity. However, an incidental finding showed a significantly increased risk of death 
for those receiving potentially curative treatment later than 40 days after CRC diagnosis.
Conclusions. In the CRCSA cohort from Johannesburg, comorbidity is uncommon, with no significant adverse effect on OS. If potentially 
curative treatment is initiated within 40 days of CRC diagnosis, OS could be improved. To fully understand the epidemiology of CRC in SA, 
population-based registries are essential, and future research should aim to identify health system failures that lead to delays in intervention 
beyond 40 days in patients with CRC.
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term (1- and 5-year) survival.[8-14] Comorbidity, defined as concurrent 
conditions present at the time of diagnosis of the index malignancy, 
not only contributes to physiological burden and poor survival, but 
also affects treatment choices.[13] With the rising incidence of CRC 
and the high burden of NCDs reported in SA, we can expect to see 
a similar trend.
Objectives
To determine whether comorbidity adversely affects overall survival 
(OS) in CRC in SA, as is seen in HICs.
The Colorectal Cancer in  
South Africa study
To address the paucity of information on CRC in SA, the Colorectal 
Cancer in South Africa (CRCSA) study was established in 2016. [15] 
It is the first prospective, longitudinal cohort study to describe 
the clinical presentation, management and outcomes of CRC in 
SA patients. The study is based in Johannesburg, Gauteng, the 
largest and wealthiest city in SA, with a population of ~5.7 million 
people. [16] The recruitment/study sites are part of the Academic 
Teaching Hospital Complex, Faculty of Health Sciences, University 
of the Witwatersrand, which comprises five state sector hospitals: 
Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani 
Baragwanath Academic Hospital, Edenvale Hospital and the 
Klerksdorp/Tshepong Complex, and one private sector hospital, 
Wits Donald Gordon Medical Centre. The state sector hospitals 
service people without medical insurance (84% of the population), 
while those who have insurance (16% of the population) access the 
private sector.[17] Participants were referred for study enrolment if 
they were aged ≥18  years, had histologically confirmed primary 
adenocarcinoma of the colon or rectum, diagnosed within the past 
12 months, and were willing and able to give written informed 
consent. Specifically, this article presents our analysis of the impact 
of comorbidity as well as other patient factors on CRC outcomes, 
including OS. Comorbidity is particularly important because our 
preliminary analyses indicate a mean age at the time of diagnosis 
of 56.6 years, which is substantially younger than cohorts described 
in HICs, suggesting that patients in our cohort may have a different 
comorbidity profile.[8-10,12,14,18]
Methods
The CRCSA cohort is a combined cross-sectional and longitudinal 
cohort of adults with CRC treated in Johannesburg, as described 
above.[15] Ethics approval for the study was obtained from the Human 
Research Ethics Committee (Medical) of the University of the 
Witwatersrand (ref. no. M150446). The cross-sectional component, 
which generates the baseline data, consists of an initial visit where 
consenting participants complete a comprehensive questionnaire 
administered by trained research assistants.
Study sample
Patients enrolled between January 2016 and July 2018, with at least 
6 months’ follow-up data, were included in this analysis; those with 
recurrence of CRC at initial presentation to a recruitment site were 
excluded. For the analysis, the following variables from the CRCSA 
study were included: (i) age at first visit (to a recruitment site); 
(ii) gender; (iii) self-reported race; (iv) socioeconomic indicators: 
number of household members, employment status, highest level 
of education (HLOE) and a list of assets in each household;[19] 
(v)  family history of cancer, defined as first-degree relatives 
diagnosed with CRC; (vi) anatomical location of the primary lesion; 
(vii) tumour staging at presentation, classified as local, regional or 
distant based on available information from the AJCC (American 
Joint Committee on Cancer classification system), TNM (done on 
histology or radiology) and Duke’s staging; (viii) urgency of surgery 
(elective or urgent/emergency); (ix) site of recruitment (hospital); 
(x) time to initial treatment, defined as time from diagnosis of CRC 
to first potentially curative treatment (analysed in approximate 
quartiles); and (xi) first potentially curative treatment (radiotherapy, 
chemotherapy, surgical, excluding palliative treatment or treatment 
of complications relating to CRC). Trained research assistants 
followed up participants telephonically at 6, 12, 24 and 36 months 
after the first visit for details related to completion of therapy, 
remission, recurrence and vital status. Participant information was 
corroborated through multidisciplinary team (MDT) meetings and 
clinical records.
Sample size
Sample size estimation was based on the key research objective, 
which was to examine the effect of comorbidity on patient 
survival. As a starting point, we used recently published survival 
data for a CRCSA study group of 60% at 3 years. Based on a 
comorbidity group comprising 10% of the total sample, with 
accrual and final follow-up periods of 2.5 years and 0.5 years, 
respectively, the detection of a hazard ratio of at least 1.8 with 80% 
power at the 5% significance level required a minimum sample 
size of 417 patients.[20,21]
Data analysis
The Charlson comorbidity index (CCI) has been validated for 
assessing the prognostic impact of comorbidity on CRC and for 
use with data collected from both administrative records and 
self-reported surveys.[8-10,22,23] As per the CCI scoring system, each 
condition, such as cardiovascular disease, diabetes or renal disease, 
is assigned a weighted score and then added to arrive at a total 
CCI score per patient. Higher CCI scores tend to be associated 
with a worse prognosis.[8-10,12,13] In the present study, an adapted 
version of the CCI was used to assess comorbidity in a once-off 
self-reported questionnaire and from patient clinical records. AIDS 
and metastatic tumours at diagnosis were excluded, solid tumours 
were defined as all solid tumours other than CRC, all liver disease 
was scored as mild (score of 1), and age was used as a covariate 
rather than part of the CCI. After arriving at individual CCI scores, 
participants were grouped into ‘no comorbidity’ (CCI score 0) and 
‘1 or more comorbidities’ (CCI score ≥1) for survival analysis.
Survival across comorbidity groups was compared by the Kaplan-
Meier method and Cox proportional hazards (PH) regression 
models. Multivariable Cox PH regression was performed to examine 
the effect of comorbidity on survival (unadjusted) and then adjusted 
for age at diagnosis, gender, ethnicity, study site (state/private), 
cancer site, urgency of presentation, stage, initial treatment, and 
time to initial treatment. Before undertaking survival analysis, 
statistical examination of the association between the covariates 
revealed that initial treatment received was strongly confounded 
with both surgical urgency and time to initial treatment, as 
expected. Consequently, these variables could not be used together 
as covariates, and surgical urgency was omitted as a covariate 
as only 9% of patients had urgent/emergency surgeries. Initial 
treatment (model 1) and time to initial treatment (model 2) were 
used separately as covariates in two adjusted models. Data analysis 
was carried out using SAS version 9.4 for Windows (SAS Institute, 
USA). A 5% significance level was used.
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Outcome was defined as all-cause mortality including both cancer-
related and non-cancer-related deaths. OS was determined from the 
date of diagnosis to the date of death or date last seen. An overall 
socioeconomic score (SES) was derived from employment status, 
HLOE, number of people in the household, and 11 household 
assets (for data collected from November 2016 onwards) using 
principal components analysis.[24] The first component was used as 
the SES score, in terms of which the lowest 40% of households were 
categorised as ‘poor’, the highest 20% as ‘rich’, and the rest as the 
‘middle’ group.[25]
Results
A total of 444 potential participants were enrolled, of whom 424 
fulfilled eligibility criteria for the analysis period. Overall, at the 
time of presentation 38.9% of participants had distant disease and 
only 19.1% had any comorbidity. Diabetes was the most frequent 
comorbidity (12.3%), followed by chronic obstructive pulmonary 
disease (4.7%) and cardiovascular disease (3.1%). Demographic, 
clinical and comorbidity characteristics are presented in Table 1. 
The mean (standard deviation) age at diagnosis was 56.6 (14.1) 
years (range 18 - 91). There were almost equal proportions of men 
and women, and half (53.5%) were self-reported as black. Malignant 
lesions were most commonly identified in the rectum (53.1%), 
followed by the left (26.6%) and right (19.1%) colon.
Survival
In our cohort, with a median follow-up time of 1.1 years, the 
unadjusted median survival was 2.0 years (95% confidence interval 
1.8 - 2.6). There was no significant difference in unadjusted and 
adjusted risk of death for the group with ≥1 comorbidities compared 
with those with no comorbidity (Table 2). Gender, ethnicity and 
location of malignancy had no impact on survival; however, study 
hospital site, tumour stage, initial treatment and time to initial 
treatment were found to have significant impact on outcome (OS). 
The effect of comorbidity and significant covariates on OS is 
illustrated by Kaplan-Meier survival plots in Fig. 1. An unexpected 
result was the significant increase in risk of death among patients 
who received treatment later than 40 days after diagnosis.
To contextualise the survival of our cohort and to benchmark 
outcomes, Table 3 sets out 1-year OS and OS by stage at presentation 
for this cohort and those in comparable studies conducted in LMICs 
and HICs. One-year OS in LMICs was inferior to rates observed in 
HICs. As expected, across all income settings, 1-year OS for patients 
with distant disease was poor. However, those who presented with 
local and regional disease in SA and India had inferior 1-year survival 
when compared with HICs.
Discussion
While most participants did not have any comorbidity by CCI 
classification, among those who did, there was no significant adverse 
effect on OS. The most common comorbid conditions observed were 
diabetes, chronic obstructive pulmonary disease and cardiovascular 
disease, in keeping with published data.[8,9,13,26,27] To the best of our 
knowledge, this is the first study of its kind from SA with our findings 
appearing to be similar to those from West and Central Africa. A CRC 
study in Kumasi, Ghana, reported a 24.9% prevalence of comorbidity, 
which did not significantly affect OS. In a cross-sectional study of 
Nigerian patients with various cancers, comorbidity occurred in 
26.9% of participants, but unfortunately there were no OS data. When 
compared with HICs, a possible explanation for the lower prevalence 
of comorbid disease in our study and other studies from SSA may 
be the younger mean ages at presentation (53 - 56 years).[27-33] Aside 
from SSA, younger mean ages (45 - 67 years) have been observed in 
South Asia, China and Brazil.[34,35] Collectively, these findings from 
LMICs contrast with those from HICs, where median ages are ~10 - 
15 years older, and comorbidity is twice as high and adversely affects 
Table 1. Demographic, clinical and comorbidity characteristics of 
the Colorectal Cancer South Africa cohort (N=424)*
Characteristic 
Age at diagnosis (years), mean (SD) (range) 56.6 (14.1) (18 - 91)
Gender, n (%)  
Male 214 (50.5)
Female 210 (49.5)
Self-reported race, n (%)  
Black 227 (53.5)
White 136 (32.1)
Indian 29 (6.8)
Coloured/mixed race 29 (6.8)
East Asian 2 (0.5)
Other 1 (0.2)
Study site,† n (%)
State 281 (66.3)
Private 143 (33.7)
SES score‡ – state, n (%)  
Poor 114 (56.4)
Middle 67 (33.2)
Rich 14 (6.9)
Missing 7 (3.5)
SES score – private, n (%)
Poor 7 (6.4)
Middle 52 (47.7)
Rich 47 (43.1)
Missing 3 (2.8)
Family history of CRC,§ n (%)
No 387 (91.3)
Yes 30 (7.1)
Missing 7 (1.7)
Site of tumour, n (%)
Colon, right 81 (19.1)
Colon, left 113 (26.7)
Rectum 225 (53.1)
Initial treatment by stage, n (%)  
Local (stage I and II) 109 (25.7)
Surgery 65 (59.6)
Radiation 32 (29.4)
Chemotherapy 8 (7.3)
No treatment 4 (3.7)
Regional (stage III) 150 (35.4)
Surgery 58 (38.7)
Radiation 67 (44.7)
Chemotherapy 15 (10.0)
No treatment 10 (6.7)
Distant (stage IV) 165 (38.9)
Surgery 39 (23.6)
Radiation 35 (21.2)
Chemotherapy 54 (32.7)
No treatment 37 (22.4)
Continued ...
385       May 2020, Vol. 110, No. 5
RESEARCH
CRC outcomes.[8-10,12,14] The 1-year OS in the present study (74%) is 
consistent with that of other LMICs (63 - 75%) but inferior to HICs 
(79 - 83%).[36-41] This trend of earlier age at presentation and poorer 
outcomes observed in SSA has also been observed in African 
Americans compared with non-Hispanic white Americans.[42]
Although comorbidity did not affect OS in the present study, our 
analysis produced other unexpected findings that warrant further 
discussion. It is well described that outcomes are universally poor 
in patients who present with an advanced (distant) stage of CRC, 
in all income settings. However, for those presenting with earlier 
disease (local or regional), outcomes in LMIC settings were worse 
than in HICs – this was clearly demonstrated in our cohort, as well 
as in a study from Mumbai, India.[39] For patients presenting with 
earlier disease, this disparity in outcomes from relatively under-
resourced LMIC settings could be explained by: (i) healthcare 
expenditure bias favouring screening, prevention and management 
of communicable diseases rather than NCDs; (ii) lack of access 
to basic chemotherapeutic agents; and (iii) poor health system 
infrastructure for managing resource-intensive illnesses.[43] CRC is a 
case in point here, as it requires substantial infrastructure (computed 
tomography, magnetic resonance imaging, colonoscopy services, 
histopathology) and integrated MDT management with capacity 
to offer any combination of radiation oncology, chemotherapy 
(including targeted therapy) and surgery of the primary tumour as 
well as liver metastases. Of relevance for the SA healthcare system, 
we demonstrated that when first treatment was delayed by longer 
than 40 days after diagnosis, the risk of dying from CRC doubled. A 
large study from Taiwan showed similar adverse effects on outcome 
with treatment delays >30 days.[44]
As well as being relatively young with little comorbidity, almost 
40% of our cohort had distant disease at time of presentation. These 
data concur with a cohort from a healthcare funder’s database in 
Johannesburg and the abovementioned studies from South Asia, 
Nigeria and Ghana, where 25 - 58% of CRC patients had advanced 
Table 2. Unadjusted and adjusted estimates of the effect of comorbidity on survival (N=395*)
Characteristic HR (95% CI), unadjusted
HR (95% CI), adjusted:  
initial treatment
HR (95% CI), adjusted:  
time to treatment
CCI group
0 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
≥1 1.3 (0.9 - 1.9) 1.4 (0.9 - 2.1) 1.4 (0.9 - 2.0)
Recruitment site
Private 1.0 (ref.) 1.0 (ref.)
State 2.6 (1.4 - 4.7) 2.4 (1.3 - 4.5)
Tumour stage
Local 1.0 (ref.) 1.0 (ref.)
Regional 1.8 (1.0 - 3.2) 1.9 (1.1 - 3.4)
Distant 2.9 (1.7 - 4.9) 3.4 (2.0 - 5.7)
Initial treatment
Surgery 1.0 (ref.)
Radiation 1.6 (0.9 - 2.9)
Chemotherapy 2.1 (1.2 - 3.6)
None 5.9 (3.3 - 10.4)
Time to treatment (days)
0 - 15 1.0 (ref.)
16 - 40 1.3 (0.7 - 2.7)
41 - 85 2.0 (1.1 - 3.7)
≥86 1.7 (0.9 - 3.1)
No treatment 6.0 (3.2 - 11.1)
HR = hazard ratio; CI = confidence interval; CCI = Charlson comorbidity index.
*N=395 because only 395 participants had complete data for both the comorbidity score and covariates.
Table 1. (continued) Demographic, clinical and comorbidity 
characteristics of the Colorectal Cancer South Africa cohort 
(N=424)*
Characteristic 
CCI score, n (%)
0 (no comorbidity) 326 (80.9)
1 or more (comorbidity) 77 (19.1)
Could not be scored owing to missing data 21
Comorbidities, n (%)
Diabetes 52 (12.3)
COPD 20 (4.7)
CVD (N=422) 13 (3.1)
 Moderate to severe kidney disease 
(N=422)
11 (2.6)
Peptic ulcer (N=422) 9 (2.1)
Liver disease (N=420) 3 (0.7)
Solid tumour (N=422) 2 (0.5)
Malignant lymphoma (N=423) 3 (0.5)
Dementia (N=423) 1 (0.2)
Leukaemia (N=423) 2 (0.2)
Connective tissue disease (N=420) 0
Hemiplegia (N=420) 0
Vital status at last contact, n (%)
Alive 267 (63.0)
Deceased: cancer related 148 (34.9)
Deceased: non-cancer related 7 (1.7)
Deceased: cause unknown 2 (0.5)
CCI = Charlson comorbidity index; COPD = chronic obstructive pulmonary disease; 
CVD = cardiovascular disease (myocardial infarction, congestive heart failure, 
cerebrovascular disease or peripheral vascular disease); CRC = colorectal cancer.
*Numbers are rounded to 1 decimal place and group totals may not add to 100%.
†Recruitment site.
‡Score derived from number of household members, employment status, highest level of 
education and a list of assets in each household.
§First-degree relatives with CRC.
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disease at presentation.[20,29,30,33,35-37] However, 
distant disease at time of presentation  is 
not unique to LMIC settings, and has been 
extensively described in HICs, albeit in 
older persons.[8,9,12,14,18] The trend of younger 
people presenting with advanced disease in 
our setting may be attributed to a number 
of contextual factors. Some pertain to an 
individual’s health-seeking behaviour, and 
others relate to health system failure that 
may occur at various levels. [17,45] These 
factors include absent/limited capa city 
for screening and prevention (even for 
unaffected family members of those with 
CRC), missed/delayed diagnosis in the 
young because healthcare practitioners 
misinterpret the signs and symptoms of 
CRC, circuitous referral mechanisms from 
primary practitioner to specialist referral 
centres, and few specialist referral facilities 
with MDTs to manage CRC.[43,46,47]
Interestingly, the rectum was the pre-
dominant location of the primary cancer 
in our cohort. This finding was analogous 
with findings in the abovementioned 
studies from LMICs, where approximately 
half of the participants had rectal cancer, 
and differed from HIC studies, where less 
than a third had rectal cancer.[29,30,33,35-37]
Study limitations and strengths
In the absence of a population-based 
cancer registry, this sample of CRC cases 
from a large urban metropole may not be 
representative of the overall SA population 
including rural patients. For survival 
outcomes, the relatively short median 
follow-up time is a limitation. Compared 
with large population-based registries in 
HICs, our sample size is relatively small, 
although analytical power was shown to 
be sufficient for the research questions 
addressed. The major strength of this study 
is the longitudinal design of the CRCSA 
cohort that enabled follow-up for survival 
data, which are lacking from many SSA 
studies.
Conclusions
Comorbidity was uncommon and had no 
significant adverse effect on OS in our 
CRCSA cohort. Our patients tended to 
present at a rela tively young age, and 
with more rectal than colon cancer. For 
those in our cohort presenting with local 
and regional disease, survival was worse 
compared with HICs. However, if colorectal 
cancer patients are treated timeously, OS 
may be improved significantly. While our 
results appear to differ from those from 
HICs, they are consistent with those from 
other LMICs, particularly in sub-Saharan 
Africa.
To fully understand the epidemiology 
of CRC in SA, population-based registries 
are essential and future research exploring 
genetic, environmental and gene-environ-
ment interactions that predispose to CRC in 
our region is needed. Population registries 
will enable development of risk scores for 
predicting risk of CRC, particularly in 
younger people. Health systems research 
would help to focus interventions to 
improve OS through early detection and 
fast-tracking for initiation of treatment 
within 40 days. The exact points of contact 
patients have with the healthcare system 
that delay management therefore need to be 
identified and addressed.
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Fig. 1. Kaplan-Meier plot of survival by (A) comorbidity and (B) time to treatment. (HR = hazard ratio; 
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